Pfizer Aktie News

Pfizer's strategy that will help it rebound from recent struggles is in full motion. It says a lot that the company continues to grow its dividend through tough times.

A report that vaccine approvals could be set to get stricter is pressuring shares of major vaccine makers.

Memo also reportedly mentions vaccines for flu and pneumonia.

NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) invites investors and the general public to view and listen to a webcast of a conference call with investment analysts at 8:00 a.m. EST on Tuesday, December 16, 2025. The purpose of the call is to provide Pfizer's full-year 2026 financial guidance. To view and listen to the webcast, visit our web site at www.pfizer.com/investors. Information on...

The FDA's top vaccine regulator outlines proposed changes to the vaccine evaluation process in an internal memo.

Drug companies face fairly normal industry dynamics that can leave them unloved on Wall Street over short periods of time. Pfizer is facing a patent cliff and is making a big move to revamp its drug pipeline.

A looming patent cliff in which Pfizer will lose patent exclusivity to a handful of drugs has combined with cratering revenue from COVID-19 treatments to drive Pfizer shares down 50% since 2022. Pfizer has two important catalysts that can help it not only survive but also thrive amid these these challenges.

Intuitive Surgical shows why now is a good time to consider buying surgical-robot competitor Medtronic. Eli Lilly helps explain why down-and-out drugmaker Pfizer could be worth a close look for long-term investors.